Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Stemline Therapeutics Inc (NASDAQ:STML)

8.71
Delayed Data
As of 3:59pm ET
 -0.50 / -5.43%
Today’s Change
8.31
Today|||52-Week Range
18.94
-48.94%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$165.5M

Company Description

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering, acquiring, developing and commercializing proprietary therapeutics that target cancer stem cells. It currently developing two clinical stage products: SL-401 and SL-701, as well as a pipeline of preclinical candidates that include SL-801. The SL-401 is a targeted therapy directed to the interleukin-3 receptor, or IL-3R, present on CSCs and tumor bulk of a variety of hematologic cancers. The SL-701 is an enhanced immunotherapy designed to activate the immune system to attack tumors. Stemline Therapeutics was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.

Contact Information

Stemline Therapeutics, Inc.
750 Lexington Avenue
New York New York 10022
P:(646) 502-2310
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Ivan BergsteinChairman, President & Chief Executive Officer
Kenneth HobermanChief Operating Officer & Secretary
David G. GioncoChief Accounting Officer & Vice President-Finance
Eric K. RowinskyChief Medical Officer, Head-Research & Development
Michael SzarekHead-Clinical & Regulatory Affairs